A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...
Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of ...
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
GlobalData on MSN2d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpointDespite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback